LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Suletud

SektorTervishoid

1.17 7.34

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.06

Max

1.17

Põhinäitajad
By Trading Economics
Sissetulek	1.8M -32M
Müük	-166K 1.7M
Kasumimarginaal	-1,852.384
Töötajad	181
EBITDA	7.9M -29M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+335.71% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	3. märts 2026

Turustatistika
By TradingEconomics
Turukapital	3.5M 129M
Eelmine avamishind	-6.17
Eelmine sulgemishind	1.17

Uudiste sentiment

By Acuity

50%

149 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. veebr 2026, 23:47 UTC

Kuumad aktsiad

Stocks to Watch: AppLovin, Cisco, Cognex, Pilgrim's Pride

11. veebr 2026, 22:59 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Grab Holdings to Buy U.S.-Based Stash Financial

11. veebr 2026, 23:54 UTC

Tulu

McDonald's Says Its Value Campaign Is Paying Off -- 2nd Update

11. veebr 2026, 23:50 UTC

Market Talk

Global Equities Roundup: Market Talk

11. veebr 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for Takaichi's Economic Steps -- Market Talk

11. veebr 2026, 23:49 UTC

Tulu

Singtel: Key Focus Areas Are Strengthening Core Businesses, Scaling Growth Engines, Building Momentum Across Regional Associates >Z74.SG

11. veebr 2026, 23:45 UTC

Tulu

Singtel: Net Exceptional Gain of S$1.15B in 3Q Primarily From Sale of Partial Stake in Bharti Airtel>Z74.SG

11. veebr 2026, 23:42 UTC

Tulu

Singtel 3Q Underlying Net Profit S$744M Vs. S$680M >Z74.SG

11. veebr 2026, 23:41 UTC

Tulu

Singtel 3Q Net S$1.89B Vs. Net S$1.32B >Z74.SG

11. veebr 2026, 23:40 UTC

Tulu

Singtel 3Q Operating Revenue S$3.66B Vs. S$3.63B >Z74.SG

11. veebr 2026, 23:35 UTC

Market Talk

Gold Falls on Prospects of Long Fed Pause -- Market Talk

11. veebr 2026, 23:18 UTC

Market Talk

AppLovin CEO Looks to Soothe Concerns Over AI, Competition -- Market Talk

11. veebr 2026, 23:14 UTC

Market Talk

RBA Governor Faces Barrage of Questions About Govt Spending -- Market Talk

11. veebr 2026, 22:59 UTC

Tulu

Kakao 2025 Net KRW525.72B Vs. Loss KRW161.87B >035720.SE

11. veebr 2026, 22:59 UTC

Tulu

Kakao 2025 Oper Pft KRW732.04B Vs. Pft KRW460.21B >035720.SE

11. veebr 2026, 22:59 UTC

Tulu

Kakao 2025 Rev KRW8.099T Vs. KRW7.872T >035720.SE

11. veebr 2026, 22:58 UTC

Tulu

Kakao 4Q Net Loss Missed FactSet-Compiled Consensus

11. veebr 2026, 22:57 UTC

Tulu

Kakao 4Q Loss KRW39.30B Vs. Loss KRW395.21B >035720.SE

11. veebr 2026, 22:54 UTC

Tulu

Kakao 4Q Oper Pft KRW203.45B Vs. Pft KRW75.43B >035720.SE

11. veebr 2026, 22:53 UTC

Tulu

Kakao 4Q Rev KRW2.133T Vs. KRW1.957T >035720.SE

11. veebr 2026, 22:47 UTC

Tulu

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11. veebr 2026, 22:47 UTC

Tulu

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11. veebr 2026, 22:23 UTC

Tulu

Grab Holdings Expects to Close Stash Acquisition in 3Q of 2026 >GRAB

11. veebr 2026, 22:22 UTC

Tulu

Grab Holdings to Acquire U.S. Digital Financial Services Company Stash Financial >GRAB

11. veebr 2026, 22:22 UTC

Tulu

Grab Holdings Sees FY26 Adj Ebitda $700M to $720M >GRAB

11. veebr 2026, 22:19 UTC

Tulu

Grab Holdings Sees FY26 Rev $4.04B to $4.10B >GRAB

11. veebr 2026, 22:18 UTC

Tulu

Grab Holdings 4Q Adj Ebitda $148.0M Vs. $97.0M >GRAB

11. veebr 2026, 22:18 UTC

Tulu

Grab Holdings 4Q Net $153.0M Vs. Net $11.0M >GRAB

11. veebr 2026, 22:18 UTC

Tulu

Grab Holdings 4Q Oper Pft $52.0M Vs. $2.0M >GRAB

11. veebr 2026, 22:16 UTC

Tulu

Grab Holdings 4Q Rev $906.0M Vs. $764.0M >GRAB

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

335.71% tõus

12 kuu keskmine prognoos

Keskmine 4.88 USD 335.71%

Kõrge 8 USD

Madal 2 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

6 ratings

Osta

Hoia

Müü

Põhineb 6 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

149 / 352 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.